Table 1.
Baseline characteristics of the study population
| n = 268 | |
|---|---|
| Age (years) | 75.1 (±11.0) |
| Sex (female), n (%) | 77 (29) |
| Smoking, n (%) | 31 (11.6) |
| BMI (kg/m2) | 27.4 (±5.6) |
| SBP (mmHg) | 137.4 (±27.7) |
| DBP (mmHg) | 79.2 (±15.3) |
| HT, n (%) | 106 (39.6) |
| AHT, n (%) | 268 (100%) |
| Beta‐blockers, n (%) | 137 (92) |
| ACEi or ARB, n (%) | 208 (78) |
| Aldosterone antagonists, n (%) | 14 (5) |
| Loop diuretics, n (%) | 258 (96) |
| Diabetes, n (%) | 105 (39) |
| Cholesterol (mmol/L) | 3.6 (1.1) |
| HDL (mmol/L) | 1.2 (0.4) |
| GFR (mL/min) | 45.9 (16.8) |
| AF, n (%) | 157 (58.6) |
| Newly diagnosed HF, n (%) | 85 (32) |
| NT‐proBNP (pmol/L) | 4077.5 [2175.0–8125.8] |
| Cystatin C | 1.6 [1.3–2.1] |
| Copeptin | 30.9 [14.7–49.2] |
| MR‐proADM | 1.6 [1.1–2.2] |
| CT‐pro‐ET‐1 | 149.3 [118.9–200.0] |
| LVEF, n (%) | 39.1 (16.2) |
ACEi, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; AHT, antihypertensive treatment; ARB, angiotensin II receptor antagonist; BMI, body mass index; CT‐pro‐ET‐1, C‐terminal pro‐endothelin‐1; DBP, diastolic blood pressure; GFR, glomerular filtration rate; HDL, high‐density lipoprotein; HF, heart failure; HT, hypertension; LVEF, left ventricular ejection fraction; MR‐proADM, mid‐regional pro‐adrenomedullin; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide; SBP, systolic blood pressure.
Values are means (± standard deviation) or median [25th–75th inter‐quartile range].